Latest Franchising News

CSL Limited’s interim CEO Gordon Naylor reveals a downgraded FY26 outlook amid slower growth and announces substantial impairments tied to CSL Vifor assets. Leadership changes and transformation efforts aim to restore momentum.

Judo Bank’s Q3 results show solid lending expansion, stable credit quality amid economic uncertainty, and reaffirmed FY26 guidance with a healthy capital buffer.

Entropy Neurodynamics has unveiled a striking 75% response rate in a small Phase 2a trial of its oral psilocybin therapy for treatment-resistant irritable bowel syndrome, far surpassing existing treatments and validating its gut-brain axis approach.

Light & Wonder (ASX:LNW) posted modest revenue growth in 2025, driven by Gaming and iGaming segments, while SciPlay revenue dipped slightly. The company completed its Grover acquisition, settled a $128 million IP dispute with Aristocrat, and transitioned to a sole ASX listing.

Woolworths Group posted a 4.5% increase in third quarter sales, led by strong Australian Food and WooliesX eCommerce growth, while signaling cautious EBIT guidance due to inflation and Middle East conflict impacts.

Streamplay Studio delivers a fourth consecutive quarter of positive cash flow, underpinned by steady publishing revenues and strategic platform growth in new regions.

Judo Bank reported solid Q3 lending growth and stable asset quality, maintaining its FY26 profit before tax guidance between $180m and $190m despite increasing credit loss provisions due to economic uncertainty.

Heartland Group Holdings Limited maintains its FY2026 guidance, reporting expanded net interest margins and improved asset quality in 3Q2026, while navigating geopolitical uncertainties affecting New Zealand and Australian markets.

Connexion Mobility reported a record $3 million quarterly revenue, boosted by exclusive software deployment for GM Canada’s Enhanced Exposure Program, while net profit before tax fell 31% due to higher expenses.

Collins Foods has formalised a settlement deed to resolve a long-running employee class action over 10-minute rest breaks, with Federal Court approval still pending.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals has broadened availability of DAYBUE STIX, a new FDA-approved powder formulation of trofinetide for Rett syndrome, in the US. Early caregiver feedback and expert consensus highlight its potential role in personalised patient care.

ImpediMed Limited has appointed Erik Anderson as its new CEO and Managing Director, effective 7 April 2026, aiming to boost commercial execution and revenue growth in the US market. Dr Parmjot Bains will remain as an advisor until 30 June 2026 to ensure a smooth leadership transition.